文献速递脊柱关节炎

强直性脊柱炎淀粉样变性的风险、预测因素与结局:一项纵向人群队列研究

The risk, predictors and outcomes of amyloidosis in ankylosing spondylitis: a longitudinal population-based cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

AS患者发生淀粉样变性的风险较对照者高6倍以上,合并症负担较重者易感性更高,合并淀粉样变性的AS患者需透析的终末期肾病风险显著升高。

要点

  • AS患者淀粉样变性发病率2.15/万 person-years,对照为0.35/万 person-years。
  • AS患者发生淀粉样变性的校正风险比6.16(95%CI 2.43, 15.62)。
  • 合并淀粉样变性的AS患者需透析的终末期肾病校正风险比14.7(95%CI 2.0, 107.2)。

核心结论

  • AS患者发生淀粉样变性的风险较匹配对照者升高6倍以上,合并淀粉样变性的AS患者透析依赖风险显著增加,而全因死亡风险差异无统计学意义。

主要发现

  • AS患者淀粉样变性发病率为2.15(95%CI 1.09, 2.82)/万 person-years,对照者为0.35(95%CI 0.16, 0.66)/万 person-years。
  • AS患者发生淀粉样变性的校正HR为6.16(95%CI 2.43, 15.62),P < 0.001。
  • 合并症负担较高可预测AS患者淀粉样变性易感性增加,OR为1.36(95%CI 1.08, 1.73),P = 0.010。
  • 合并淀粉样变性的AS患者需透析的终末期肾病校正HR为14.7(95%CI 2.0, 107.2),P = 0.008。
  • 合并淀粉样变性的AS患者全因死亡校正HR为2.16(95%CI 0.69, 6.71),P = 0.174。

临床怎么用

  • 对AS患者应关注淀粉样变性这一并发症,尤其合并症负担较高者,并监测肾功能以警惕透析依赖风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The risk of amyloidosis during the course of AS is yet to be firmly established. We aimed to evaluate the risks, predictors and prognostic outcomes of amyloidosis among patients with AS. METHODS: A population-based cohort study was conducted comparing AS patients (n = 5911) with age-, sex- and ethnicity-matched control subjects (n = 29 007) with regard to incident cases of amyloidosis. Hazard ratios (HRs) and odds ratios (ORs) were estimated by Cox regression and logistic regression analyses, respectively. RESULTS: The incidence rate of amyloidosis was 2.15 (95% CI 1.09, 2.82) and 0.35 (95% CI 0.16, 0.66) per 10 000 person-years among patients with AS and controls, respectively. The risk of incident amyloidosis was >6-fold higher among patients with AS relative to control subjects [adjusted HR 6.16 (95% CI 2.43, 15.62); P < 0.001]. A higher comorbidity burden [OR 1.36 (95% CI 1.08, 1.73); P = 0.010] was found to predict an increased susceptibility to amyloidosis in AS patients. Compared with other patients with AS, those with AS and comorbid amyloidosis had a 14-fold increased risk of end-stage renal disease necessitating dialysis [adjusted HR 14.7 (95% CI 2.0, 107.2); P = 0.008], but comparable risk of all-cause mortality [adjusted HR 2.16 (95% CI 0.69, 6.71); P = 0.174]. CONCLUSIONS: Patients with AS are at an increased risk of amyloidosis. AS-associated amyloidosis is associated with an elevated risk of dialysis dependence. Awareness of the burden and consequences of this complication may be of help for rheumatologists managing patients with AS.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kridin M, Kridin K, Cohen AD, et al. The risk, predictors and outcomes of amyloidosis in ankylosing spondylitis: a longitudinal population-based cohort study. Rheumatology (Oxford). 2022. PMID: 34373900. doi:10.1093/rheumatology/keab633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。